Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CNS-focused Arvelle spins off from Axovant with planned $100mm initial round

Executive Summary

Axovant Sciences Ltd. spun off its small-molecule platform assets into a new company, Arvelle Therapeutics GMBH, which received commitments for an initial capital raise of over $100mm (assumed to be its Series A round) from a syndicate of investors, including NovaQuest Capital Management, Life Science Partners, BRV Capital Management, Andera Partners, and HIG BioHealth Partners.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Preliminary
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies